Telix Theranostic Programs and Satellite Symposia on Innovation in PSMA and CAIX Imaging Featured at SNMMI 2025

Core Insights - Telix Pharmaceuticals Limited is showcasing its innovative pipeline and commercial products at the SNMMI 2025 Annual Meeting, emphasizing its commitment to advancing cancer care through precision theranostics [1][3]. Group 1: Presentation Highlights - The ProstACT Global Phase 3 study of TLX591 in advanced prostate cancer will be presented, along with preclinical data on TLX252 alpha therapy in CAIX-expressing tumors [2]. - Clinical study data on the impact of Illuccix® on decision-making will also be featured [2]. - Two sponsored symposia will focus on CAIX-PET imaging in renal cancer and Illuccix PSMA-PET imaging in prostate cancer, including a new PSMA biopsy trial [2]. Group 2: Presentation Details - Key presentations include a Phase 3 study of TLX591 in combination with standard care for PSMA-expressing prostate cancer, scheduled for June 23 [4]. - Another presentation will discuss the enhanced antitumor efficacy of DNA damage response inhibitors combined with TLX252, taking place on June 24 [4]. - A prospective comparison of Ga-PSMA-11 PET/CT and Tc-PSMA-GCK01/RHN001DX SPECT/CT will also be presented [4]. Group 3: Satellite Symposia - The first symposium will address CAIX-PET imaging in renal cancer, scheduled for June 23 [6]. - The second symposium will focus on innovations in prostate cancer care with precision radiopharmaceuticals, also on June 23 [6]. Group 4: Company Overview - Telix is a biopharmaceutical company dedicated to developing therapeutic and diagnostic radiopharmaceuticals, headquartered in Melbourne, Australia, with operations in multiple countries [7]. - The company aims to address significant unmet medical needs in oncology and rare diseases through its clinical and commercial stage products [7]. - Illuccix®, Telix's first-generation PSMA-PET imaging agent, has received approval in various countries, while TLX591, TLX252, and RHN001Dx are still awaiting marketing authorization [8].